Neonatal Respiratory Distress Syndrome Treatment Market Report 2025

This Neonatal Respiratory Distress Syndrome Treatment market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The neonatal respiratory distress syndrome treatment market size has grown strongly in recent years. It will grow from $0.96 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to factors such as the rising permeability and fluid accumulation in the alveoli, an increase in alveolar-capillary permeability, a higher utilization of mechanical ventilation, greater awareness among healthcare providers and parents about the importance of neonatal care, and increased investments in healthcare.

The neonatal respiratory distress syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $1.41 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to factors such as the rising demand for accessories and consumables, an increase in NICU admissions, a growing need for personalized medicine, a higher rate of premature births, and expanding research and development activities. Key trends expected in the forecast period include the automation of neonatal intensive care units (NICUs), the integration of artificial intelligence (AI), advancements in neonatal care technology, innovations in surfactant therapy, and the development of advanced ventilator technologies.

The growing incidence of premature births is expected to drive the expansion of the neonatal respiratory distress syndrome (NRDS) treatment market. Premature birth, or preterm birth, occurs when a baby is born before 37 weeks of pregnancy, with those born before 32 weeks facing the greatest health risks, as a typical pregnancy lasts about 40 weeks. The rise in premature births is attributed to factors such as advancing maternal age, multiple pregnancies, medical conditions, lifestyle choices, fertility treatments, infections, and environmental influences. Neonatal respiratory distress syndrome is commonly seen in premature infants due to their underdeveloped lungs and insufficient surfactant production. Treatment for NRDS helps improve lung function, stabilize breathing, and lower the risk of respiratory failure in preterm babies. For example, Tommy's, a UK-based charity, reported in December 2022 that the percentage of premature live births in England and Wales increased to 7.9% in 2022 from 7.5% in 2021, marking a second consecutive year of rising premature births, with over 53,000 babies born prematurely that year. As a result, the growing incidence of premature births is fueling the growth of the NRDS treatment market.

Leading companies in the neonatal respiratory distress syndrome treatment market are focusing on the development of advanced technologies such as nitric oxide generators to improve oxygenation, reduce respiratory complications, and provide non-invasive treatment options for neonates with hypoxic respiratory failure. A nitric oxide generator is a device that produces and administers nitric oxide gas, which is used to treat respiratory issues by enhancing oxygenation and reducing pulmonary hypertension, especially in neonates and critically ill patients. For example, in June 2022, Beyond Air Inc., a US-based medical device and biopharmaceutical company, received FDA approval for its LungFit PH. This innovative nitric oxide generator is designed to treat term and near-term neonates with hypoxic respiratory failure, including persistent pulmonary hypertension of the newborn (PPHN). The device utilizes Beyond Air's patented Ionizer technology to generate nitric oxide on demand from ambient air, providing a continuous supply without concerns about dosage or flow. It also uses a low-power compressor to ionize nitrogen and oxygen, minimizing the production of nitrogen dioxide (NO2), which is then safely filtered out using a smart filter.

In January 2024, Chiesi Group, an Italy-based biopharmaceutical company, entered into a partnership with Oak Hill Bio to advance neonatal therapies. This collaboration aims to develop and commercialize OHB-607, an innovative treatment designed to prevent severe bronchopulmonary dysplasia (BPD) and its long-term respiratory complications in preterm infants, especially those born before 28 weeks gestational age with low IGF-1 levels. Oak Hill Bio is a UK-based company focused on developing treatments for neonatal and rare diseases.

Major players in the neonatal respiratory distress syndrome treatment market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Medtronic Plc, Medline Industries, Becton Dickinson, Stryker Corporation, GE Healthcare, Koninklijke Philips NV, ResMed Inc., Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, ICU Medical Inc., Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Aerogen Pharma Corp., Windtree Therapeutics Inc., Discovery Laboratories Inc., and Lyomark Pharma GmbH.

North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neonatal respiratory distress syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neonatal respiratory distress syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neonatal respiratory distress syndrome (NRDS) treatment focuses on managing premature infants who experience breathing difficulties due to inadequate surfactant production. This treatment typically includes the administration of exogenous surfactant therapy, respiratory support through mechanical ventilation or continuous positive airway pressure (CPAP), and oxygen supplementation.

The primary treatments for neonatal respiratory distress syndrome are oxygen therapy and surfactant therapy. Oxygen therapy involves supplying oxygen to patients who struggle to get enough oxygen through normal breathing. It can be delivered via parenteral routes, inhalation, or other methods, and is used in hospitals, sub-acute facilities, home care settings, and retail pharmacies.

The neonatal respiratory distress syndrome treatment market research report is one of a series of new reports that provides neonatal respiratory distress syndrome treatment market statistics, including neonatal respiratory distress syndrome treatment industry global market size, regional shares, competitors with a neonatal respiratory distress syndrome treatment market share, detailed neonatal respiratory distress syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neonatal respiratory distress syndrome treatment industry. This neonatal respiratory distress syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neonatal respiratory distress syndrome treatment market consists of revenues earned by entities by providing services such as surfactant administration services, neonatal respiratory care consulting, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The neonatal respiratory distress syndrome treatment market also includes sales of mechanical ventilators, continuous positive airway pressure (CPAP) machines, high-frequency ventilators, and neonatal incubators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.